FindTrial
Sign In

68Ga-NNS309

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Colorectal CancerColorectal Cancer (CRC)HR+/HER2- Ductal Breast Cancer (BC)HR+/HER2- Ductal and Lobular Breast CancerHR+/HER2- Lobular Breast Cancer (BC)Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)Non-Small Cell Lung CancerNon-small Cell Lung Cancer (NSCLC)

Phase 1

Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
RecruitingNCT07261631
Novartis PharmaceuticalsColorectal Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Non-Small Cell Lung Cancer +3
Start: 2025-11-24End: 2029-05-09Target: 180Updated: 2026-06-17
Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors
RecruitingNCT07630961
Novartis PharmaceuticalsColorectal Cancer (CRC), HR+/HER2- Ductal Breast Cancer (BC), HR+/HER2- Lobular Breast Cancer (BC) +4
Start: 2026-06-23End: 2028-01-16Target: 66Updated: 2026-08-27